The use of omegaven in treating parenteral nutrition-associated liver disease

Journal of Perinatology

Volumn 31, Issue , 2011, Pages S57-S60

  Nespor, C ^a   Kerner, J ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fish oil; Lipid emulsion; Omega 3; Omegaven; Parenteral nutrition associated cholestasis; Parenteral nutrition associated liver disease

Indexed keywords

ARACHIDONIC ACID; FISH OIL; INTRALIPID; LIPOSYN II; OMEGA 3 FATTY ACID; OMEGAVEN; PHYTOSTEROL; SOYBEAN OIL; TUMOR NECROSIS FACTOR ALPHA;

CHOLESTASIS; CRITICALLY ILL PATIENT; FOLIC ACID DEFICIENCY; HUMAN; HYPERBILIRUBINEMIA; LIVER DISEASE; LIVER FIBROSIS; LIVER PROTECTION; NONHUMAN; PARENTERAL NUTRITION; PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS; PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE; REVIEW; SHORT BOWEL SYNDROME;

CHOLESTASIS; FAT EMULSIONS, INTRAVENOUS; FATTY ACIDS, OMEGA-3; HUMANS; INFANT; INFANT, NEWBORN; LIVER DISEASES; PARENTERAL NUTRITION; SHORT BOWEL SYNDROME;

EID: 79953318464     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2010.182     Document Type: Article

References (30)

1. Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson DS et al. Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes. J Pediatr 2001; 139(1): 27-33.
2. Wales PW, de Silva N, Kim J, Lecce L, To T, Moore A. Neonatal short bowel syndrome: population-based estimates of incidence and mortality rates. J Pediatr Surg 2004; 39(5): 690-695.
3. Freund HR. Abnormalities of liver function and hepatic damage associated with total parenteral nutrition. Nutrition 1991; 7(1): 1-5; discussion 5-6.
4. Zambrano E, El-Hennawy M, Ehrenkranz RA, Zelterman D, ReyesMu´gicaM. Total parenteral nutrition induced liver pathology: an autopsy series of newborn cases. Pediatr Dev Pathol 2004; 7(5): 425-432.
5. Christensen RD, Henry E, Wiedmeier SE, Burnett J, Lambert DK. Identifying patients, on the first day of life, at high-risk of developing parenteral nutrition-associated liver disease. J Perinatol 2007; 27(5): 284-290.
6. Willis TC, Carter BA, Rogers SP, Hawthorne KM, Hicks PD, Abrams SA. High rates of mortality and morbidity occur in infants with parenteral nutrition-associated cholestasis. JPEN J Parenter Enteral Nutr 2010; 34(1): 32-37.
7. Tazuke Y, Kiristioglu I, Heidelberger KP, Eisenbraun MD, Teitelbaum DH. Hepatic P-glycoprotein changes with total parenteral nutrition administration. JPEN J Parenter Enteral Nutr 2004; 28(1): 1-6.
8. Tulikoura I, Huikuri K. Morphological fatty changes and function of the liver, serum free fatty acids, and triglycerides during parenteral nutrition. Scand J Gastroenterol 1982; 17(2): 177-185.
9. Kelly DA. Liver complications of pediatric parenteral nutritionFepidemiology. Nutrition 1998; 14(1): 153-157.
10. Javid PJ, Greene AK, Garza J, Gura K, Alwayn IP, Voss S. et al. The route of lipid administration affects parenteral nutrition-induced hepatic steatosis in a mouse model. J Pediatr Surg 2005; 40(9): 1446-1453.
11. Colomb V, Jobert-Giraud A, Lacaille F, Goulet O, Fournet JC, Ricour C. Role of lipid emulsions in cholestasis associated with long-term parenteral nutrition in children. JPEN J Parenter Enteral Nutr 2000; 24(6): 345-350.
12. Wanten GJ, Calder PC. Immune modulation by parenteral lipid emulsions. Am J Clin Nutr 2007; 85(5): 1171-1184.
13. Grimminger F, Wahn H, Mayer K, Kiss L, Walmrath D, Seeger W. Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. Am J Respir Crit Care Med 1997; 155(2): 513-519.
14. Clayton PT, Whitfield P, Iyer K. The role of phytosterols in the pathogenesis of liver complications of pediatric parenteral nutrition. Nutrition 1998; 14(1): 158-164.
15. Hallikainen M, Huikko L, Kontra K, Nissinen M, Piironen V, Miettinen T et al. Effect of parenteral serum plant sterols on liver enzymes and cholesterol metabolism in a patient with short bowel syndrome. Nutr Clin Pract 2008; 23(4): 429-435.
16. Zaman N, Tam YK, Jewell LD, Coutts RT. Effects of intravenous lipid as a source of energy in parenteral nutrition associated hepatic dysfunction and lidocaine elimination: a study using isolated rat liver perfusion. Biopharm Drug Dispos 1997; 18(9): 803-819.
17. Carter BA, Taylor OA, Prendergast DR, Zimmerman TL, Von Furstenberg R, Moore DD et al. Stigmasterol, a soy lipid-derived phytosterol, is an antagonist of the bile acid nuclear receptor FXR. Pediatr Res 2007; 62(3): 301-306.
18. Van Aerde JE, Duerksen DR, Gramlich L, Meddings JB, Chan G, Thomson AB et al. Intravenous fish oil emulsion attenuates total parenteral nutrition-induced cholestasis in newborn piglets. Pediatr Res 1999; 45(2): 202-208.
19. Alwayn IP, Gura K, Nose´ V, Zausche B, Javid P, Garza J et al. Omega-fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res 2005; 57(3): 445-452.
20. Cavicchi M, Beau P, Crenn P, Degott C, Messing B. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med 2000; 132(7): 525-532.
21. Heller AR, Rossler S, Litz RJ, Stehr SN, Heller SC, Koch R. et al. Omega-fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 2006; 34(4): 972-979.
22. Gura KM, Parsons SK, Bechard LJ, Henderson T, Dorsey M, Phipatanakul W et al. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr 2005; 24(5): 839-847.
23. de Meijer VE, Le HD, Meisel JA, Gura KM, Puder M. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition-dependent patients. J Pediatr Gastroenterol Nutr 2010; 50(2): 212-218.
24. Gura KM, Duggan CP, Collier SB, Jennings RW, Folkman J, Bistrian BR et al. Reversal of parenteral nutrition-associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management. Pediatrics 2006; 118(1): e197-e201.
25. Gura KM, Lee S, Valim C, Zhou J, Kim S, Modi BP et al. Safety and efficacy of a fishoil- based fat emulsion in the treatment of parenteral nutrition-associated liver disease. Pediatrics 2008; 121(3): e678-e686.
26. Puder M, Valim C, Meisel JA, Le HD, de Meijer VE, Robinson EM et al. Parenteral fish oil improves outcomes in patients with parenteral nutrition-associated liver injury. Ann Surg 2009; 250(3): 395-402.
27. Diamond IR, Sterescu A, Pencharz PB, Kim JH, Wales PW. Changing the paradigm: omegaven for the treatment of liver failure in pediatric short bowel syndrome. J Pediatr Gastroenterol Nutr 2009; 48(2): 209-215.
28. Malone FR, Javid PJ, Davis C, Jacob S, Reyes JD, Healey PJ et al. Impaired glucose production and b-cell dysfunction contribute to the disturbed metabolism in children with protein-energy malnutrition. J Pediatr Gastroenterol Nutr 2009; 49(Supplement 1): E38.
29. Soden JS, Lovell MA, Brown K, Partrick DA, Sokol RJ. Failure of resolution of portal fibrosis during omega-fatty acid lipid emulsion therapy in two patients with irreversible intestinal failure. J Pediatr 2010; 156(2): 327-331.
30. Yang CF, Lee M, Valim C, Hull MA, Zhou J, Jones BA et al. Persistent alanine aminotransferase elevations in children with parenteral nutrition-associated liver disease. J Pediatr Surg 2009; 44(6): 1084-1087; discussion 1087-8.